Note 1 - Summary of Significant Accounting Policies (Details Textual)		12 Months Ended
	Apr. 19, 2023	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jul. 31, 2023	Dec. 31, 2021 USD ($)
Number of Tumor Samples		150,000
Number of Reportable Segments		3
Retained Earnings (Accumulated Deficit)		$ (167,761,883)	$ (153,777,916)
Cash and Cash Equivalents, at Carrying Value		8,728,660	22,071,523
Liabilities, Current		3,951,031	3,882,670
Accounts Payable and Accrued Liabilities, Current		2,973,729
Operating Lease, Liability, Current		517,427	94,237
Notes Payable, Current		$ 150,408	0
Short-Term Debt, Percentage Bearing Fixed Interest Rate		9.25%		9.25%
Operating Lease, Liability, Noncurrent		$ 2,188,979	$ 86,082
Operating Lease, Weighted Average Remaining Lease Term (Year)		3 years 11 months 26 days	1 year 8 months 19 days
Net Cash Provided by (Used in) Operating Activities		$ (13,189,390)	$ (12,370,800)
Accounts Receivable, Allowance for Credit Loss, Current		0	0
Accounts Receivable, after Allowance for Credit Loss, Total		333,697	331,196		$ 354,196
Contract with Customer, Liability		313,550	602,073		$ 186,951
Contract with Customer, Liability, Revenue Recognized		277,767
Research and Development Expense, Total		188,305	$ 320,320
Unrecognized Tax Benefits		0
Cash, Uninsured Amount		$ 142,118
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20